ABSI Strangle Strategy
ABSI (Absci Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSI (Absci Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $826.3M, a beta of 2.38 versus the broader market, a 52-week range of 2.24-6.72, average daily share volume of 4.3M, a public-listing history dating back to 2021, approximately 156 full-time employees. These structural characteristics shape how ABSI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.38 indicates ABSI has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on ABSI?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ABSI snapshot
As of May 15, 2026, spot at $5.14, ATM IV 89.10%, IV rank 31.10%, expected move 25.54%. The strangle on ABSI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ABSI specifically: ABSI IV at 89.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 25.54% (roughly $1.31 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABSI expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABSI should anchor to the underlying notional of $5.14 per share and to the trader's directional view on ABSI stock.
ABSI strangle setup
The ABSI strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABSI near $5.14, the first option leg uses a $5.40 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABSI chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABSI shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $5.40 | N/A |
| Buy 1 | Put | $4.88 | N/A |
ABSI strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ABSI strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ABSI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ABSI
Strangles on ABSI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABSI chain.
ABSI thesis for this strangle
The market-implied 1-standard-deviation range for ABSI extends from approximately $3.83 on the downside to $6.45 on the upside. A ABSI long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ABSI IV rank near 31.10% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on ABSI should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ABSI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABSI-specific events.
ABSI strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABSI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABSI alongside the broader basket even when ABSI-specific fundamentals are unchanged. Always rebuild the position from current ABSI chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ABSI?
- A strangle on ABSI is the strangle strategy applied to ABSI (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ABSI stock trading near $5.14, the strikes shown on this page are snapped to the nearest listed ABSI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ABSI strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ABSI strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 89.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABSI strangle?
- The breakeven for the ABSI strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABSI market-implied 1-standard-deviation expected move is approximately 25.54%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ABSI?
- Strangles on ABSI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABSI chain.
- How does current ABSI implied volatility affect this strangle?
- ABSI ATM IV is at 89.10% with IV rank near 31.10%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.